[go: up one dir, main page]

AR043674A1 - Derivados de piridazinona como inhibidores no nucleosidos de la transcriptasa reversa - Google Patents

Derivados de piridazinona como inhibidores no nucleosidos de la transcriptasa reversa

Info

Publication number
AR043674A1
AR043674A1 ARP040100938A ARP040100938A AR043674A1 AR 043674 A1 AR043674 A1 AR 043674A1 AR P040100938 A ARP040100938 A AR P040100938A AR P040100938 A ARP040100938 A AR P040100938A AR 043674 A1 AR043674 A1 AR 043674A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
aminoalkyl
thioalkyl
cycloalkyl
Prior art date
Application number
ARP040100938A
Other languages
English (en)
Inventor
James Patrick Dunn
Brian William Dymock
Taraneh Mirzadegan
Eric Brian Sjogren
Steven Swallow
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR043674A1 publication Critical patent/AR043674A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente se refiere a los métodos para inhibir o modular la transcriptasa inversa el virus de la inmunodeficiencia humana (VIH) con compuestos de fórmula (1) composiciones farmacéuticas que contienen la fórmula (1) en mezcla con al menos un disolvente, vehículo o excipiente y procedimientos para preparar los compuestos de fórmula (1). Los compuestos son útiles para tratar los trastornos en que VIH y los virus genéticamente relacionados están implicados. Reivindicación 1: Un compuesto de acuerdo con la fórmula (1): X1 se selecciona del grupo que consiste de R5O, R5S(O)n, R5CH2, R5CH2O, R5CH2S(O)n, R5OCH2, R5S(O)nCH2, NR5R6; R1 y R2 son (i) cada uno independientemente seleccionado del grupo que consiste de H, C1-6 alquilo, C1-6 haloalquilo, C3-8 cicloalquilo, C1-6 alcoxilo, C1-6 tioalquilo, C1-6 sulfinilalquilo, C1-6 sulfonilo, C1-6 haloalcoxilo, C1-6 tiohaloalquilo, halógeno, amina, aminoalquilo, diaminoalquilo, aminoacilo, nitro y ciano; o (ii) cogidos juntamente son -CH=CH-CH=CH-; o (iii) cogidos junto con los carbonos a los que están unidos forman un anillo heterocíclico o heteroaromático de 6 o 5 miembros con uno o dos heteroátomos independientemente seleccionados del grupo que consiste en O, S y NH; R3 se selecciona del grupo que consiste de H, C1-6 alquilo, C1-6 haloalquilo, C3-8 cicloalquilo, C1-6 tioalquilo, C1-6 tiohaloalquilo, halógeno, amina, alquilamino, dialquilamino, aminoacilo, nitro y ciano; R4 se selecciona del grupo que consiste de H, C1-6 alquilo, C1-6 haloalquilo, C3-8 cicloalquilo, C1-6 alcoxi, C1-6 tioalquilo, C1-6 haloalcoxilo, C1-6 tiohaloalquilo, halógeno, amina, aminoalquilo, dialquilamino, aminoacilo, nitro y ciano; R5 se selecciona del grupo que consiste de alquilo, haloalquilo, cicloalquilo, fenilo, naftilo, piridinilo, pirazinilo y pirrolilo; en donde, dicho alquilo y dicho cicloalquilo están opcionalmente sustituido con un o dos sustituyentes independientemente seleccionados del grupo que consiste de alquilo, hidroxilo, alcoxilo, tiol, tioalquilo, halógeno, amina, aminoalquilo, diaminoalquilo, aminoalquilo, alquilaminoalquilo, y diaminoalquilo, y, dicho fenilo, dicho naftilo, dicho piridinilo, dicho pirazinilo y dichos grupos pirrolilo están opcionalmente sustituidos con de uno a tres sustituyentes independientemente seleccionados del grupo que consiste de C1-6 alquilo, C1-6 alquenilo, C1-6 haloalquilo, C3-8 cicloalquilo, C1-6 alcoxilo, C1-6 tioalquilo, C1-6 sulfinilalquilo, C1-6 sulfonilo, C1-6 haloalcoxilo, C1-6 tiohaloalquilo, hidroxilo, halógeno, amina, C1-6 aminoalquilo, C1-6diaminoalquilo, aminoacilo, acilo, C1-6 alcoxicarbonilo, carbamoilo, C1-6 N-alquilcarbamoilo, C1-6 N,N-dialquilcarbamoilo, nitro y ciano; R6 es H, C1-6 alquilo, o acilo; R7 y R8 (i) cogidos independientemente son seleccionados del grupo que consiste de amino hidrógeno, C1-6 aminoalquilo, C1-6 diaminoalquilo, amino-C1-3 alquilo, aminoalquilo-C1-3 alquilo, C1-3 diaminoalquilo-C1-3 alquilo o C1-6 alquilo opcionalmente sustituidos con un o dos sustituyentes independientemente seleccionados del grupo que consiste de hidroxilo, alcoxilo, tiol, tioalquilo, C1-6 sulfinilalquilo, C1-6 sulfonilo y halógeno, N-morfolinil; o (ii) R7 y R8 cogidos juntamente son -(CH2)4-; n es un número entero de 0 a 2; e hidratos, solvatos, clatratos y sales de adición ácida de los mismos.
ARP040100938A 2003-03-24 2004-03-22 Derivados de piridazinona como inhibidores no nucleosidos de la transcriptasa reversa AR043674A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45714403P 2003-03-24 2003-03-24

Publications (1)

Publication Number Publication Date
AR043674A1 true AR043674A1 (es) 2005-08-03

Family

ID=33098202

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100938A AR043674A1 (es) 2003-03-24 2004-03-22 Derivados de piridazinona como inhibidores no nucleosidos de la transcriptasa reversa

Country Status (13)

Country Link
US (1) US7189718B2 (es)
EP (1) EP1608629A1 (es)
JP (1) JP4485520B2 (es)
KR (1) KR20050119652A (es)
CN (1) CN100469769C (es)
AR (1) AR043674A1 (es)
AU (1) AU2004224191A1 (es)
BR (1) BRPI0408704A (es)
CA (1) CA2518823A1 (es)
MX (1) MXPA05010081A (es)
RU (1) RU2344128C2 (es)
TW (1) TW200505453A (es)
WO (1) WO2004085406A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2005090317A1 (en) * 2004-03-23 2005-09-29 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
WO2005100323A1 (en) * 2004-04-15 2005-10-27 F. Hoffmann-La Roche Ag Process for preparing pyridazinone compounds
US7700640B2 (en) * 2004-10-16 2010-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423042D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Chemical process
EP1863777A1 (en) * 2005-03-24 2007-12-12 F.Hoffmann-La Roche Ag 1,2,4 -triazole-5-one compounds as heterocyclic reverse transcriptase inhibitors
JP4651714B2 (ja) 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体
CN101228135B (zh) * 2005-07-21 2011-08-31 霍夫曼-拉罗奇有限公司 作为甲状腺激素受体激动剂的哒嗪酮衍生物
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
EP1937651B1 (en) * 2005-09-30 2008-12-24 F.Hoffmann-La Roche Ag Nnrt inhibitors
CA2625047A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
WO2008019968A1 (en) * 2006-08-16 2008-02-21 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
BRPI0809617A2 (pt) * 2007-03-29 2014-09-16 Hoffmann La Roche Inibidores não-nucleosídicos da transcriptase reversa
MX2009010932A (es) * 2007-04-09 2009-10-29 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.
CN101663292A (zh) 2007-04-23 2010-03-03 詹森药业有限公司 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物
MX2009011416A (es) 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
AU2008257771B2 (en) 2007-05-30 2015-02-19 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
JP2010530863A (ja) * 2007-06-22 2010-09-16 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としての尿素及びカルバマート誘導体
AU2008322676B9 (en) 2007-11-15 2014-03-27 Msd Italia S.R.L. Pyridazinone derivatives as PARP inhibitors
MX2010005483A (es) 2007-11-20 2010-06-11 Merck Sharp & Dohme Inhibidores de transcriptasa inversa no nucleosidos.
WO2009067597A1 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf 4- (or 5-) substituted catechol derivatives
EP2225239B1 (en) * 2007-12-21 2014-10-22 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
AU2009275887B2 (en) 2008-07-31 2013-06-20 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
AU2009298981B2 (en) 2008-10-02 2012-09-27 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and use thereof
ME02181B (me) 2010-03-30 2015-10-20 Merck Canada Inc Ne-nukleozidni inhibitori reverzne transkriptaze
CN102731410B (zh) * 2012-07-06 2014-07-30 山东大学 一种哒嗪类hiv-1逆转录酶抑制剂的制备与应用
ES2907926T3 (es) 2012-09-17 2022-04-27 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
LT3125894T (lt) 2014-04-01 2020-12-10 Merck Sharp & Dohme Corp. Živ atvirkštinės transkriptazės inhibitorių provaistai
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
CN110167557A (zh) 2016-10-18 2019-08-23 马德里加尔制药公司 用thr-beta兴奋剂治疗肝脏疾病或脂质疾病的方法
CN109053693B (zh) * 2018-09-20 2021-02-05 顺毅股份有限公司 哒嗪胺类化合物的制备及其应用
MA54549A (fr) 2018-12-18 2022-03-30 Merck Sharp & Dohme Dérivés de pyrimidone en tant qu'agents cytotoxiques sélectifs contre des cellules infectées par le vih
US20220251021A1 (en) * 2019-07-01 2022-08-11 Ascentawits Pharmaceuticals, Ltd. Akr1c3 inhibitor and medical use
CN116003253A (zh) * 2022-12-31 2023-04-25 上海试四化学品有限公司 一种三氟苯嘧啶中间体2-[3-(三氟甲基)苯基]丙二酸二甲酯的制备方法
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4949314A (en) 1966-08-16 1990-08-14 The United States Of America As Represented By The Secretary Of The Navy Method and means for increasing echo-ranging-search rate
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4780480A (en) 1983-07-14 1988-10-25 Syntex (U.S.A.) Inc. Aroyl benzofuran and benzothiophene acetic and propionic acids
GB8327880D0 (en) 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
AU622926B2 (en) 1988-09-09 1992-04-30 Nippon Kayaku Kabushiki Kaisha Pyrimidine or purine cyclobutane derivatives
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US5489697A (en) 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
PL183931B1 (pl) 1994-09-26 2002-08-30 Shionogi & Co Nowe związki, pochodne imidazolu i kompozycje farmaceutyczne je zawierające
EP0809490A4 (en) 1995-02-10 1999-10-20 Smithkline Beecham Corp USE OF LCK SH2 SPECIFIC COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND ALLOPLASTIC STOPPING REACTIONS
AU4788396A (en) 1995-02-16 1996-09-04 Children's Medical Center Corporation Inhibition of angiogenesis using interleukin-12
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
IL117574A0 (en) 1995-04-03 1996-07-23 Bristol Myers Squibb Co Processes for the preparation of cyclobutanone derivatives
EP0871436A4 (en) 1995-06-30 1999-10-20 Smithkline Beecham Corp USE OF STAT 6 SH2 DOMAINE-SPECIFIC COMPOUNDS FOR TREATING ALLERGIC REACTIONS
JPH10512585A (ja) 1995-06-30 1998-12-02 スミスクライン・ビーチャム・コーポレイション 赤血球形成を増強するためのｓｔａｔ ５ ｓｈ２領域特異性化合物の使用
CN1136197C (zh) 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 新的哒嗪酮衍生物
CN1303378A (zh) * 1998-04-27 2001-07-11 国家科研中心 3－(氨基－或氨基烷基)吡啶酮衍生物和它们在hiv相关疾病治疗中的用途
WO2001085670A1 (en) 2000-05-12 2001-11-15 Kissei Pharmaceutical Co., Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and use thereof
GB0024795D0 (en) 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
BRPI0208811B8 (pt) 2001-04-10 2021-05-25 Pfizer derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors

Also Published As

Publication number Publication date
EP1608629A1 (en) 2005-12-28
TW200505453A (en) 2005-02-16
RU2005132630A (ru) 2006-07-27
AU2004224191A1 (en) 2004-10-07
JP4485520B2 (ja) 2010-06-23
RU2344128C2 (ru) 2009-01-20
US7189718B2 (en) 2007-03-13
JP2006521310A (ja) 2006-09-21
KR20050119652A (ko) 2005-12-21
CA2518823A1 (en) 2004-10-07
CN1764649A (zh) 2006-04-26
BRPI0408704A (pt) 2006-03-07
MXPA05010081A (es) 2005-11-23
WO2004085406A1 (en) 2004-10-07
CN100469769C (zh) 2009-03-18
US20040198736A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
AR043674A1 (es) Derivados de piridazinona como inhibidores no nucleosidos de la transcriptasa reversa
AR043673A1 (es) Compuestos heterociclicos inhibidores no nucleosidos de la transcriptasa inversa i, preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del sida
RU2345996C1 (ru) Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
EA201100975A1 (ru) Производные 1,2,4-оксадиазола и их применение в терапии
AR036598A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen potente actividad antagonista de cb1
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
EA200970171A1 (ru) Производные n-(аминогетероарил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
AR004219A1 (es) Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios
AR039127A1 (es) Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
AR030558A1 (es) COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA,
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
RU2008126245A (ru) Комбинация ингибитора асне и антагониста 5-нт для лечения когнитивной дисфункции
AR045557A1 (es) Sintesis selectivas de pirimidinas sustituidas con cf3
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR030424A1 (es) Derivados de 6-fenilpirrol[3,2-d] pirimidina y de 6-fenilpirrol[2,3-d]-pirimidin-2,4-diona; procedimientos de preparacion de dichos derivados; compuestos intermediarios de aplicacion en la preparacion de dichos derivados y el uso de los mismos en el tratamiento del cuerpo humano y/o de animales y/o
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR045156A1 (es) Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR066605A1 (es) Derivados de heteroarilamida pirimidona
AR041882A1 (es) Compuestos de imidazopiridina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ECSP088257A (es) Derivados de amida
HRP20080119T5 (en) Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same
RU2009114731A (ru) Производное пиразолопиримидина
AR054863A1 (es) DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA

Legal Events

Date Code Title Description
FB Suspension of granting procedure